摘要
[目的]检测Keap1-Nrf2-ARE信号通路相关蛋白在胃腺癌组织中的表达,探讨其作用和临床意义。[方法]选择64例胃腺癌组织,对应的癌旁组织为对照,应用免疫组织化学的方法检测癌组织及对照组织中细胞核因子E2相关因子2 (Nrf2)以及抗氧化应答元件(ARE)的表达。[结果]胃癌组织中Nrf2、ARE的表达水平分别为1.78±0.34、1.69±0.45,均显著高于癌旁组织(0.47±0.16、0.52±0.22),差异有统计学意义(P<0.001)。胃癌低/中分化患者中,Nrf2、 ARE的阳性表达率分别为79.1%、88.4%,均显著高于高分化患者(P<0.05);TNM分期Ⅲ、Ⅳ期患者Nrf2、ARE的阳性表达率分别为81.4%和90.7%,均显著高于Ⅰ、Ⅱ期患者,差异有统计学意义(P<0.05);有淋巴结转移患者Nrf2、ARE的阳性率分别为80.5%和92.7%,显著高于无淋巴结转移的患者(P<0.05)。相关性分析显示Nrf2与ARE蛋白在胃腺癌组织中的表达呈显著正相关(χ2=17.322,P<0.001)。[结论 ]胃腺癌患者癌组织中Nrf2与ARE蛋白表达上调,Keap1-Nrf2-ARE信号通路与胃腺癌的发生发展密切相关。
[Objective]To investigate the expression of Keap1-Nrf2-ARE signaling pathway-related protein in gastric adenocarcinoma and its clinical significance.[Method]The expression of nuclear factor E2-related factor 2(Nrf2)and anti-oxidant responsive element(ARE)in 64 samples of gastric adenocarcinoma and the corresponding adjacent tissues were detected with immunohistochemistry.[Results]The expression levels of Nrf2 and ARE in cancer tissues were 1.78±0.34 and 1.69±0.45,which were significantly higher than those in adjacent tissues(P<0.05).The positive rates of Nrf2 and ARE in poor and moderately differentiated tumors was 79.1%and 88.4%in cancer tissues,which were higher than those in well differentiated tumors(P<0.05).The positive rates of Nrf2 and ARE was 81.4%and 90.7%in TNM stageⅢandⅣpatients,which were significantly higher than those in stageⅠandⅡgastric adenocarcinoma.(P<0.05).In patients with lymph node metastasis,the positive rates of Nrf2 and ARE was 80.5%and 92.7%,which were significantly higher than those of patients without lymph node metastasis(P<0.05).Correlation analysis showed a significant positive correlation between Nrf2 and ARE protein expression in gastric adenocarcinoma tissues(χ2=17.322,P<0.001).[Conclusion]The expression of Nrf2 and ARE protein are up-regulated in the cancer tissues of patients with gastric adenocarcinoma,indicating that Keap1-Nrf2-ARE signaling pathway may be closely related to the occurrence and development of gastric adenocarcinoma.
作者
沈磊
张平平
杨海涛
SHEN Lei;ZHANG Ping-ping;YANG Hai-tao(The Third People’s Hospital of Hefei,Hefei 230001,China;Basic Medical College of Anhui Medical University,Hefei 230001,China;Third Affiliated Hospital of Anhui Medical University,Hefei 230001,China)
出处
《肿瘤学杂志》
CAS
2019年第8期703-706,共4页
Journal of Chinese Oncology
基金
安徽省自然科学基金青年项目(1808085QH277)
